Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Deborah Wexler MD, MSc

Deborah J. Wexler MD, MSc

Associate Professor of Medicine, Harvard Medical School; Chief, Diabetes Unit, Massachusetts General Hospital, Boston, Massachusetts

Dr. Deborah J. Wexler is Associate Professor of Medicine at Harvard Medical School and Chief of the Massachusetts General Hospital Diabetes Unit.

Dr. Wexler’s research focuses on clinical effectiveness in type 2 diabetes. She has led multiple National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)– and Patient-Centered Outcomes Research Institute (PCORI)– funded projects that seek to improve the health and well-being of people with diabetes. Dr Wexler is on the editorial board of Diabetes Care, is a reviewer for multiple medical journals, and is an editor of NIDDK’s Diabetes in America.

She received her medical degree from Yale University School of Medicine, New Haven, Connecticut, and completed her internship, residency, and chief residency in internal medicine and fellowship in endocrinology at Massachusetts General Hospital in Boston.

Disclosures

  • Data monitoring committees: Novo Nordisk (for trials of oral semaglutide)

Recent Contributions to PracticeUpdate:

  1. ADA 2018: Diabetes Care Guidelines
  2. ADA 2018: Cystic Fibrosis Related Diabetes
  3. ADA Scientific Sessions 2018: Recommendations From Dr. Deborah Wexler
  4. Long-Term Outcomes Associated With Triple-Goal Achievement in Patients With Type 2 Diabetes
  5. Cardiovascular Outcomes Associated With Canagliflozin vs Other Non-Gliflozin Antidiabetic Drugs
  6. Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events
  7. 2017 Top Stories in Diabetes: EXSCEL in Context
  8. Incidence and Clinical Characteristics of Diabetes Following Pancreatic Disease
  9. Lifestyle Interventions Improve Glycemic Control in Type 2 Diabetes
  10. Glucose Self-Monitoring in Non–Insulin Treated Patients With Type 2 Diabetes Does Not Improve Glycemic Control

Elsewhere

Recently Updated